XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net loss $ (1,906) $ (1,773)
Adjustments to reconcile net loss to net cash used in operating activities:    
Loss on disposition of Tantaline 162
Impairment charge 111
Stock-based compensation 647 307
Depreciation and amortization 545 538
Changes in assets and liabilities, net of effects of disposition of Tantaline:    
Accounts receivable 1,163 (1,404)
Contract assets (725) (614)
Inventories (1,756) (909)
Tax receivable 716
Employee retention credit receivable 1,529
Other current assets (46) (66)
Accounts payable 113 363
Accrued expenses (729) 687
Contract liabilities 816 (173)
Net cash used in operating activities (76) (2,328)
Cash flows from investing activities:    
Net cash used in connection with disposition of Tantaline (312)
Deposits from purchaser of MesoScribe assets 597
Purchases of property and equipment (308) (638)
Capitalized patents costs (53)
Net proceeds from sale of assets 10
Net cash used in investing activities (23) (681)
Cash flows from financing activities    
Proceeds from exercise of stock options 76
Payments of long-term debt (57) (1,766)
Net cash provided by (used in) financing activities 19 (1,766)
Net decrease in cash and cash equivalents (80) (4,775)
Cash and cash equivalents at beginning of period 14,365 16,651
Cash and cash equivalents at end of period 14,285 11,876
Supplemental disclosure of cash flow information:    
Income taxes paid 11 1
Interest paid 18 8
Non-cash investing and financing activities:    
Loan obtained for new equipment $ 432